Effects and mechanisms of PPARα activator fenofibrate on myocardial remodelling in hypertension

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 11-12, 2009, Pages 4444-4452

  Li, Chuan Bao ^a   Li, Xiao Xing ^a   Chen, Yu Guo ^a   Zhang, Cheng ^a   Zhang, Ming Xiang ^a   Zhao, Xue Qiang ^a   Hao, Ming Xiu ^a   Hou, Xiao Yang ^a   Gong, Mao Lei ^b   Zhao, Yu Xia ^a   Bu, Pei Li ^a   Zhang, Yun ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Cardiac remodelling; Fenofibrate; Hypertension; Peroxisome proliferator activated receptor

Indexed keywords

RATTUS;

COLLAGEN; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN C FOS; PROTEIN C JUN;

ANIMAL; ARTICLE; DRUG EFFECT; ECHOGRAPHY; GENETICS; HEART MUSCLE; HEART VENTRICLE REMODELING; HEMODYNAMICS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; ULTRASTRUCTURE; WISTAR KYOTO RAT;

ANIMALS; COLLAGEN; HEMODYNAMICS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDIUM; PPAR ALPHA; PROCETOFEN; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RATS; RATS, INBRED SHR; RATS, INBRED WKY; VENTRICULAR REMODELING;

EID: 77951151606     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00484.x     Document Type: Article

References (34)

1. Hayden MR, Chowdhury N, Govindarajan G. Myocardial myocyte remodeling and fibrosis in the cardiometabolic syndrome. J Cardiometab Syndr. 2006, 1:326-33.
2. Ogata T, Miyauchi T, Sakai S. Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci. 2002, 103(Suppl 48):284S-8S.
3. Grove D, Zak R, Nair KG. Biochemical correlates of cardiac hypertrophy, observations on the cellular organization of growth during myocardial hypertrophy in the rat. Circ Res. 1969, 25:473-85.
4. Heeneman S, Cleutjens JP, Faber BC. The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. J Pathol. 2003, 200:516-25.
5. Doering CW, Jalil JE, Janicki JS. Collagen network remodeling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res. 1988, 22:686-95.
6. Jalil JE, Doering CW, Janicki JS. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res. 1989, 64:1041-50.
7. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990, 347:645-50.
8. Braissant O, Foufelle F, Scotto C. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996, 137:354-66.
9. Schoonjans K, Martin G, Staels B. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997, 8:159-66.
10. Kliewer SA, Sundseth SS, Jones SA. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA. 1997, 94:4318-23.
11. Xu HE, Lambert MH, Montana VG. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell. 1999, 3:397-403.
12. Delerive P, De Bosscher K, Besnard S. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem. 1999, 274:32048-54.
13. Barger PM, Brandt JM, Leone TC. Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth. J Clin Invest. 2000, 105:1723-30.
14. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene. 2001, 20:2390-400.
15. Sahn DJ, DeMaria A, Kisslo J. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978, 58:1072-83.
16. Di Paola R, Di Guardo G, Lo Giudice P. Preclinical thalassemic cardiopathy: a study by acoustic densitometry. Ital Heart J. 2003, 4:413-8.
17. Cingolani OH, Yang XP, Cavasin MA. Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats. Hypertension. 2003, 41:249-54.
18. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques. 1993, 15:536-7.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (delta delta CT-method). Methods. 2001, 25:402-8.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72:248-54.
21. Albaladejo P, Carusi A, Apartian A. Effect of chronic heart rate reduction with ivabradine on carotid and aortic structure and function in normotensive and hypertensive rats. J Vasc Res. 2003, 40:320-8.
22. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of intracardiac renin-angiotensin system. Annu Rev Physiol. 1992, 54:227-41.
23. Miyata S, Haneda T. Hypertrophic growth of cultured neonatal rat heart cells mediated by type I angiotensin II receptor. Am J Physiol. 1994, 266:H2443-51.
24. Zhang YG, Li YG, Liu BG. Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol Sin. 2007, 28:36-43.
25. Kokubo M, Uemura A, Matsubara T. Noninvasive evaluation of the time course of change in cardiac function in spontaneously hypertensive rats by echocardiography. Hypertens Res. 2005, 28:601-9.
26. Liang F, Wang F, Zhang S. Peroxisome proliferator activated receptor (PPAR) alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology. 2003, 144:4187-94.
27. Bakiri L, Matsuo K, Wisniewska M. Promoter specificity and biological activity of tethered AP-1 dimers. Mol Cell Biol. 2002, 22:4952-64.
28. Eghbali M, Tomek R, Sukhatme VP. Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res. 1991, 69:483-90.
29. Armendariz-Borunda J, Simkevich CP, Roy N. Activation of Ito cells involves regulation of AP-1 binding proteins and induction of type I collagen gene expression. Biochem J. 1994, 304:817-24.
30. Philips N, Bashey RI, Jiménez SA. Increased alpha 1(I) procollagen gene expression in tight skin (TSK) mice myocardial fibroblasts is due to a reduced interaction of a negative regulatory sequence with AP-1 transcription factor. J Biol Chem. 1995, 270:9313-21.
31. Iglarz M, Touyz RM, Viel EC. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension. 2003, 42:737-43.
32. Liang F, Wang F, Zhang S. Peroxisome proliferator activated receptor (PPAR) alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology. 2003, 144:4187-94.
33. Irukayama-Tomobe Y, Miyauchi T, Sakai S. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation. 2004, 109:904-10.
34. Chen J, Mehta JL. Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol. 2006, 291:H1738-45.